Pacira Biosciences Inc
PCRX26.020USD
+0.280+1.09%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.12BMarket Cap
55.98P/E TTM
More Details of Pacira Biosciences Inc Company
Pacira BioSciences, Inc. is the holding company for its subsidiary, Pacira Pharmaceuticals, Inc. The Company has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis.
Pacira Biosciences Inc Info
Ticker SymbolPCRX
Company namePacira Biosciences Inc
IPO dateFeb 03, 2011
CEOLee (Frank D)
Number of employees790
Security typeOrdinary Share
Fiscal year-endFeb 03
Address2000 Sierra Point Parkway
CityBRISBANE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94005
Phone16502428052
Websitehttps://www.pacira.com/
Ticker SymbolPCRX
IPO dateFeb 03, 2011
CEOLee (Frank D)
Company Executives of Pacira Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Mark A. Kronenfeld, M.D.
Dr. Mark A. Kronenfeld, M.D.
Independent Director
Independent Director
34.90K
+40.15%
Mr. Daryl Gaugler
Mr. Daryl Gaugler
Executive Vice President - Commercial Operations
Executive Vice President - Commercial Operations
32.29K
-51.29%
Dr. Jonathan Slonin, M.D.
Dr. Jonathan Slonin, M.D.
Chief Medical Officer
Chief Medical Officer
30.41K
-11.52%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Chairman of the Board
Independent Chairman of the Board
23.71K
+35.11%
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
Independent Director
Independent Director
9.04K
-20.66%
Ms. Lauren Riker
Ms. Lauren Riker
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
5.98K
-59.94%
Mr. Michael J. Yang
Mr. Michael J. Yang
Independent Director
Independent Director
--
--
Mr. Shawn M. Cross
Mr. Shawn M. Cross
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Marcelo Bigal, M.D., Ph.D.
Dr. Marcelo Bigal, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Susan Mesco
Ms. Susan Mesco
Investor Relations
Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Mark A. Kronenfeld, M.D.
Dr. Mark A. Kronenfeld, M.D.
Independent Director
Independent Director
34.90K
+40.15%
Mr. Daryl Gaugler
Mr. Daryl Gaugler
Executive Vice President - Commercial Operations
Executive Vice President - Commercial Operations
32.29K
-51.29%
Dr. Jonathan Slonin, M.D.
Dr. Jonathan Slonin, M.D.
Chief Medical Officer
Chief Medical Officer
30.41K
-11.52%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Chairman of the Board
Independent Chairman of the Board
23.71K
+35.11%
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
Independent Director
Independent Director
9.04K
-20.66%
Ms. Lauren Riker
Ms. Lauren Riker
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
5.98K
-59.94%
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
EXPAREL
142.92M
0.00%
ZILRETTA
31.33M
0.00%
iovera
5.59M
0.00%
Bupivacaine liposome injectable suspension
508.00K
0.00%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
EXPAREL
142.92M
0.00%
ZILRETTA
31.33M
0.00%
iovera
5.59M
0.00%
Bupivacaine liposome injectable suspension
508.00K
0.00%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
14.84%
The Vanguard Group, Inc.
11.96%
DOMA Perpetual Capital Management, LLC
6.83%
Dimensional Fund Advisors, L.P.
5.03%
Renaissance Technologies LLC
4.97%
Other
56.38%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
14.84%
The Vanguard Group, Inc.
11.96%
DOMA Perpetual Capital Management, LLC
6.83%
Dimensional Fund Advisors, L.P.
5.03%
Renaissance Technologies LLC
4.97%
Other
56.38%
Shareholder Types
Shareholders
Proportion
Investment Advisor
53.03%
Investment Advisor/Hedge Fund
26.31%
Hedge Fund
25.79%
Research Firm
5.60%
Pension Fund
2.58%
Individual Investor
1.52%
Bank and Trust
0.91%
Holding Company
0.36%
Sovereign Wealth Fund
0.04%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
596
52.11M
121.12%
-15.93M
2025Q2
613
53.27M
118.43%
-16.03M
2025Q1
638
53.73M
116.03%
-16.46M
2024Q4
638
52.13M
112.66%
-21.91M
2024Q3
638
53.62M
116.22%
-11.06M
2024Q2
624
54.29M
116.65%
-6.10M
2024Q1
627
51.47M
110.71%
-7.99M
2023Q4
621
50.55M
108.88%
-6.71M
2023Q3
612
49.73M
107.18%
-6.05M
2023Q2
605
49.27M
107.14%
-5.45M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
6.69M
14.89%
-72.97K
-1.08%
Jun 30, 2025
The Vanguard Group, Inc.
5.36M
11.92%
+165.93K
+3.20%
Jun 30, 2025
DOMA Perpetual Capital Management, LLC
2.70M
6.01%
+894.55K
+49.59%
Aug 05, 2025
Dimensional Fund Advisors, L.P.
2.15M
4.79%
+102.21K
+4.99%
Jun 30, 2025
Renaissance Technologies LLC
2.40M
5.33%
--
--
Jun 30, 2025
D. E. Shaw & Co., L.P.
2.25M
5.01%
-10.54K
-0.47%
Jun 30, 2025
State Street Investment Management (US)
1.95M
4.34%
-28.76K
-1.45%
Jun 30, 2025
Balyasny Asset Management LP
2.13M
4.74%
+565.29K
+36.11%
Jun 30, 2025
American Century Investment Management, Inc.
1.18M
2.63%
+515.09K
+77.18%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.14M
2.54%
+5.66K
+0.50%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco Pharmaceuticals ETF
2.2%
State Street SPDR S&P Pharmaceuticals ETF
1.62%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.53%
ETC 6 Meridian Small Cap Equity ETF
0.94%
Simplify Health Care ETF
0.8%
Pacer US Small Cap Cash Cows Growth Leaders ETF
0.75%
Invesco S&P SmallCap Health Care ETF
0.59%
VictoryShares Small Cap Free Cash Flow ETF
0.59%
Invesco NASDAQ Future Gen 200 ETF
0.43%
Distillate Small/Mid Cash Flow ETF
0.41%
View more
Invesco Pharmaceuticals ETF
Proportion2.2%
State Street SPDR S&P Pharmaceuticals ETF
Proportion1.62%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.53%
ETC 6 Meridian Small Cap Equity ETF
Proportion0.94%
Simplify Health Care ETF
Proportion0.8%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proportion0.75%
Invesco S&P SmallCap Health Care ETF
Proportion0.59%
VictoryShares Small Cap Free Cash Flow ETF
Proportion0.59%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.43%
Distillate Small/Mid Cash Flow ETF
Proportion0.41%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Pacira Biosciences Inc?
The top five shareholders of Pacira Biosciences Inc are:
BlackRock Institutional Trust Company, N.A. holds 6.69M shares, accounting for 14.89% of the total shares.
The Vanguard Group, Inc. holds 5.36M shares, accounting for 11.92% of the total shares.
DOMA Perpetual Capital Management, LLC holds 2.70M shares, accounting for 6.01% of the total shares.
Dimensional Fund Advisors, L.P. holds 2.15M shares, accounting for 4.79% of the total shares.
Renaissance Technologies LLC holds 2.40M shares, accounting for 5.33% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.69M shares, accounting for 14.89% of the total shares.
The Vanguard Group, Inc. holds 5.36M shares, accounting for 11.92% of the total shares.
DOMA Perpetual Capital Management, LLC holds 2.70M shares, accounting for 6.01% of the total shares.
Dimensional Fund Advisors, L.P. holds 2.15M shares, accounting for 4.79% of the total shares.
Renaissance Technologies LLC holds 2.40M shares, accounting for 5.33% of the total shares.
What are the top three shareholder types of Pacira Biosciences Inc?
The top three shareholder types of Pacira Biosciences Inc are:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
DOMA Perpetual Capital Management, LLC
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
DOMA Perpetual Capital Management, LLC
How many institutions hold shares of Pacira Biosciences Inc (PCRX)?
As of 2025Q3, 596 institutions hold shares of Pacira Biosciences Inc, with a combined market value of approximately 52.11M, accounting for 121.12% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 2.69%.
What is the biggest source of revenue for Pacira Biosciences Inc?
In FY2025Q2, the EXPAREL business generated the highest revenue for Pacira Biosciences Inc, amounting to 142.92M and accounting for --% of total revenue.
